1974 Volume 48 Issue 9 Pages 357-368
Propionylmaridomycin (PMDM) is a new macrolide-series antibiotic developed by the Research Laboratories of the Takeda Chemical Ind. Ltd., in 1972. Pharmacological and bacteriological studies have shown this agent to have an antibacterial activity almost equal to that of kitasamycin (LM) both in vitro and in vivo.
The study was carried out in order to compare the clinical effect of PMDM, by double blind method, in respiratory infectious diseases (bacterial pneumoniae, acute bacterial bronchitis, acute tonsillitis) with that of LM as the control; 29 patients with bacterial pneumoniae were treated by 1600mg of PMDM or LM daily for 2 weeks; 38 patients with acute bacterial bronchitis and 32 patients with acute tonsillitis were treated by daily dose of 1200mg of PMDM or LM for 1 week.
The following results were obtained.
1) Improvement of main symptomes of bacterial pneumoniae was observed in 11 of 16 patients treated with PMDM (68.8%) and in 9 of 13 patients treated with LM (69.2%).
Improvement of main symptoms of acute bacterial bronchitis was observed in 14 of 22 patients in PMDM group (63.6%) and in 11 of 16 patients in LM group (68.8%).
Improvement of main symptomes of acute tonsillitis was observed in 9 of 14 patients in PMDM group (64.3%) and in 15 of 18 patients in LM group (88.9%). The clinical effect of both antibiotics showed no significant difference.
2) Gastrointestinal disturbance was main side effect and no severe side effects, such as fever, skin rash, anaemia, toxic hepatits were observed in both PMDM group and LM group.
